Clearside Biomedical Q2 2024 Adj EPS $(0.10) Beats $(0.13) Estimate, Sales $90.00K Miss $152.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Clearside Biomedical (NASDAQ:CLSD) reported Q2 2024 adjusted EPS of $(0.10), beating the $(0.13) estimate. However, sales of $90.00K missed the $152.00K estimate and decreased 91.16% year-over-year.
August 12, 2024 | 8:16 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Clearside Biomedical reported better-than-expected EPS for Q2 2024 but missed sales estimates significantly. Sales also dropped 91.16% year-over-year.
While the EPS beat expectations, the significant miss in sales and the drastic year-over-year decline in revenue are likely to negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100